Phase 2 trials of vandetanib in pretreated patients with advanced RET-rearranged NSCLC demonstrated variable anticancer activity with overall response rates (ORRs) ranging from 18% to 50% [117]. This evidence concerns the gene RET and non-small cell lung carcinoma.